Kurkumin ve Gastrointestinal Sistem Hastalıkları

Zerdeçalın başlıca kimyasal bileşenlerinden biri olan kurkumin [1,7-bis (4-hidroksi-3-metoksifenil) -1,6-heptadien-3,5-dion], Curcuma Longa bitkisinin rizomundan kaynatma, kurutma gibi işlemler ile üretilir. Kurkumin farmakolojik olarak, Çin ve Hindistan tıbbında yaklaşık 6000 yıldır geleneksel bir tıbbi ajan olarak kullanılmaktadır. Gıda ve İlaç İdaresi (FDA) kurkumini “genellikle güvenli olarak tanınan” bir bileşik olarak onaylanmıştır. Çalışmalar ile kurkuminin bağırsak mikrobiyotası üzerine etki ederek yarar sağlayabileceği öngörülmektedir. Bazı çalışmalar kurkuminin, inflamasyonu baskılaması başta olmak üzere, çeşitli mekanizmalar aracılığıyla, inflamatuvar bağırsak hastalıkları, kolorektal kanser ve hepatik fibroz dahil olmak üzere H.pylori, pankreatit ve gut permeabilitesini sağlamada yararlı etkilere sahip olduğunu göstermiştir. Besin-ilaç etkileşimleri ve gebe, laktasyon ve çocuklarda kurkumin kullanımındaki belirsizlikler ve çalışma sonuçlarındaki farklılıklar da göz önüne alındığında, gastointestinal hastalıklarda kurkuminin etkisini açıklamak için daha fazla çalışmaya ihtiyaç duyulmaktadır.

Anahtar Kelimeler:

kurkumin, gastointestinal hastalıklar, zerdeçal

Curcumin and Gastrointestinal System Diseases

Curcumin [1,7-bis (4-hydroxy-3-methoxyphenyl) -1,6-heptadiene-3,5-dione], one of the main chemical components of turmeric, is produced from the rhizome of the Curcuma longa plant by processes such as boiling and drying. Curcumin has been used pharmacologically as a tradi- tional medicinal agent in Chinese and Indian medicine for nearly 6000 years. The Food and Drug Administration (FDA) approved curcumin as a “generally recognized as safe” compound. Studies suggest that curcumin may benefit by acting on intestinal microbiota. Some studies have shown that curcumin has beneficial effects in promoting permeability of H. pylori, pancreatitis, and gout, including inflammatory bowel dise- ase, colorectal cancer, and hepatic fibrosis, through a variety of mechanisms, notably by suppressing inflammation. Considering the food-drug interactions and the uncertainties in the use of curcumin in pregnant, lactation and children, and the differences in study results, more studies are needed to explain the effect of curcumin in gastrointestinal diseases.

Keywords:

Curcumin, gastrointestinal diseases, turmeric,

PDF

___

1. Beevers CS, Huang S. Pharmacological And Clinical Properties Of Curcumin. Botanics. 2011; (1): 5–18.
2. Hassan, Snur. Curcuma longa, turmeric: A monograph. Aust. J. Medical Herbal. 2016; 18: 66-76.
3. Kostalova D, Bezakova L, Rackovac L et. al. Therapeutic Potential of Curcumin In Medicinal Chemistry. Acta Chimica Slovaca. 2013; 6(1):88-99.
4. Lopresyti AL. The Problem Of Curcumin And Its Bioavailability: Could Its Gastrointestinal In Uence Contribute To Its Overall Health-Enhancing Effects?. Adv Nutr. 2018; 9: 41–50.
5. Prasad S, Gupta S, Tyagi A et. al. Curcumin, a Component of Golden Spice: From Bedside to Bench and Back. Biotechnol. Adv. 2014; 32:1053-1064.
6. Kocaadam B, Şanlıer N. Curcumin, An Active Component Of Turmeric (Curcuma Longa), And Its Effects On Health. Crit Rev Food Sci Nutr. 2017; 57: 13.
7. İçen H, Güneş E. Kurkumı̇n ve İmmün Sistem Üzerine Etkı̇lerı̇. DBHAD.2017; 3: (7).
8. Lestari M, Indrayanto G. Curcumin. Profiles Drug Subst Excip Relat Methodol. 2014; 39:113-204.
9. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C et. al. Curcumin and Health. Molecules. 2016; 21:264.
10. Liu W, Zhai Y, Heng X et. al. Oral Bioavailability of Curcumin: Problems and Advancements. J. Drug Target. 2016.
11. Karaman BE, Köseler E. Zerdeçalın Kronik Hastalıklarla İlişkisi. BÜSBİD. 2017; 2: (2).
12. Brumatti LV, Marcuzzi A, Tricarico PM et. al. Curcumin and Inflammatory Bowel Disease: Potential and Limits of Innovative Treatments. Molecules. 2014; 19.
13. Rajkumari S, Sanatombi K. Nutritional value, phytochemical composition, and biological activities of edible Curcuma species: A review. Int J Food Prop. 2017; 20: (3).
14. Hewlings S, Kalman D. Curcumin: A Review of Its' Effects on Human Health. Foods. 2017; 6: (92). doi:10.3390/foods6100092.
15. Dublecco P, Savarino V. Therapeutic potential of curcumin in digestive diseases. World J Gastroenterol. 2013; 19: (48).
16. Zam W. Gut Microbiota as a Prospective Therapeutic Target for Curcumin: A Review of Mutual Influence. J Nutr Metab. 2018. Doi: https://doi.org/10.1155/2018/1367984.
17. Zeng Z, Zhan L, Liao H et. al. Curcumin improves TNBS- induced colitis in rats by inhibiting IL-27 expression via the TLR4/ NF-kappaB signaling pathway. Planta Med. 2013; 79 (2):102–109.
18. Ali T, Shakir F, Morton J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion. 2012; 85 (4): 249–55.
19. Patcharatrakul T, Gonlachanvit S. Chili Peppers, Curcumins, and Prebiotics in Gastrointestinal Health and Disease. Curr Gastroenterol Rep. 2016; 18: (19).
20. Mazieiro R, Frizon RR, Barbalho SM et. al. İs curcumin a Possibility to Treat Inflammatory Bowel Diseases?. J Med Food. 2018; (1–9). doi: 10.1089/jmf.2017.0146.
21. Lang A, Salomon N, Wu JCY et. al. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin. Gastroenterol. Hepatol. 2015; 13 :1444–1449.
22. Kedia S. Bhatia V, Thareja S et. al. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther. 2017; 6 (2): 147-154.
23. Iqbal U, Anwar H, Quadri AA. Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis. Am J Med Sci. 2018; 356 (4) : 350 356.
24. Singla V, Mouli VP, Garg SK et. al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - A randomized, placebo-controlled, pilot study. J Crohns Colitis. 2014; 8 : 208–214.
25. Garg SK, Ahuja V, Sankar MJ et. al. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012 ; 10. DOI: 10.1002/14651858.CD008424.pub2.
26. Grammatikopoulou MG, Gkiouras K, Theodoridis X et. al. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2018;10:1737. doi:10.3390/nu10111737.
27. Schneider A, Hossain I, VanderMolen J et. al. Comparison of remicade to curcumin for the treatment of Crohn’s disease: A systematic review. Complement Ther Med. 2017;33: 32-38.
28. Can G, Yılmaz B. İrritabl Barsak Sendromunun Tanı ve Tedavisinde Yaklaşımlar. Güncel Gastroenteroloji. 2015 (19): 3.
29. Ng QX, Soh AYS, Loke W et. al. A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS). J. Clin. Med.. 2018; 7: 298; doi:10.3390/jcm7100298.
30. Lauche R, Kumar S, Hallman J et. al. Efficacy and safety of Ayurvedic herbs in diarrhoea-predominant irritable bowel syndrome: A randomised controlled crossover trial. Complement Ther Med. 2016. http://dx.doi.org/doi:10.1016/j.ctim.2016.04.002.
31. David L, Wahbeh G, Burpee T et. al. Tolerability of Curcumin in Pediatric Inflammatory Bowel Disease: A forced dose titration study. J Pediatr Gastroenterol Nutr. 2013; 56(3): 277–279. doi:10.1097/MPG.0b013e318276977d.
32. He Y, Yue Y, Zheng X et. al. Curcumin, Inflammation, and Chronic Diseases: How Are They Linked?. Molecules. 2015; 20: 9183-9213.
33. Gulcubuk A, Haktanir D, Cakiris A et. al. Effects of curcumin on proinflammatory cytokines and tissue injury in the early and late phases of experimental acute pancreatitis. Pancreatology. 2013; 13: 347–354.
34. Dhillon N, Aggarwal BB, Newman RA et. al. Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer. Clin Cancer Res. 2008;14 (14).
35. Nabavi SF, Daglia M, Moghaddam AH et. al. Curcumin and Liver Disease: from Chemistry to Medicine. Compr. Rev. Food Sci. Food Saf. 2014, 13:62-77.
36. Farzaei MH, Zobeiri M, Parvizi F et. al. Curcumin in Liver Diseases: A Systematic Review of the Cellular Mechanisms of Oxidative Stress and Clinical Perspective. Nutrients. 2018; 10: 855; doi:10.3390/nu10070855.
37. Saadati S, Hatami B, Yari Z et. al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur. J. Clin. Nutr. 2019. https://doi.org/10.1038/s41430-018-0382-9.
38. Riccardo BA, Riccardo S, Salvatore N et. al. The role of curcumin in liver diseases. Arch Med Sci. 2017. DOI:https://doi.org/10.5114/aoms.2018.73596.
39. Akila G, Rajakrishnan V, Viswanathan P et. al. Effects of curcumin on lipid profile and lipid peroxidation status in experimental hepatic fibrosis. Hepatol. Res. 1998; 11: 147–157.
40. Bruck R, Ashkenazi M, Weiss S et. al. Prevention of liver cirrhosis in rats by curcumin. Liver Int. 2007; 27 :373–383.
41. Kyung EJ, Kim HB, Hwang ES et. al. Evaluation of Hepatoprotective Effect of Curcumin on Liver Cirrhosis Using a Combination of Biochemical Analysis and Magnetic Resonance-Based Electrical Conductivity Imaging. Mediators Inflamm. 2018. https://doi.org/10.1155/2018/5491797.
42. Supriono İ, Nugraheni A, Kalim H et. al. The Effect of Curcumin on Regression of Liver Fibrosis through Decreased Expression of Transforming Growth Factor-β1 (TGF-β1). Indones Biomed J. 2019; 11(1): 52-58.
43. Devassy JG, Nwachukwu ID, Jones PJH. Curcumin and cancer: barriers to obtaining a health claim. Nutr. Rev. 2015.; 73(3):155–165.
44. Park J, Conteas CN. Anti-carcinogenic properties of curcumin on colorectal cancer. World J Gastrointest Oncol. 2010; 15: 2(4): 169-176. 45. Sharma RA, Euden SA, Platton SL et. al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004; 10: 6847-6854.
46. He ZY, Shi CB, Wen H et. al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011;29: 208–213.
47. Carroll RE. Et. al. Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia. Cancer Prev Res. 2011; 4(3).
48. Garcea G, Berry DP, Jones DJL et. al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. 2005; 14: 120-125.
49. Cruz-Correa M, Shoskes DA, Sanchez P et. al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006; 4:1035-1038.
50. Sarkar A, De R, Mukhopadhyay AK. Curcumin as a potential therapeutic candidate for Helicobacter pylori associated diseases. World J Gastroenterol. 2016; 7 22(9): 2736-2748.
51. Kwiecien S. Curcumin: A Potent Protectant against Esophageal and Gastric Disorders. Int. J. Mol. Sci. 2019; 20. Doi:10.3390/ijms20061477.
52. Vetvicka V, Vetvicka J, Fernandez-Botran R. Effects of curcumin on Helicobacter pylori infection. Ann Transl Med. 2016;4(24):479.
53. Khonche A, Biglarian O, Panahi Y et. al. Adjunctive therapy with curcumin for peptic ulcer: A randomized controlled trial. Drug. Res. (Stuttg.). 2016; 66: 444–448.
54. De R, Kundu P, Swarnakar S et. al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob. Agents Chemother. 2009; 53: 1592–1597.
55. Mario FD, Cavallaro LG, Nouvenne A et. al. A Curcumin-Based 1-Week Triple Therapy for Eradication of Helicobacter pylori Infection: Something to Learn From Failure?. Helicobacter. 2007; 12: 238–243.
56. Becit M, Aydın S, Başaran N. Kurkuminin Terapötik ve Toksik Etkilerinin Değerlendirilmesi. Türkiye Klinikleri J Pharm Sci. 2017;6(2):126-42.